Imagine a world where Alzheimer's disease could be stopped in its tracks before it even starts stealing memories—this breakthrough might just make that a reality! Dive into this exciting discovery from Northwestern University that's rewriting the rules of Alzheimer's research, and you'll see why early action could be the game-changer we've all been waiting for.
In a groundbreaking animal study, a promising experimental drug named NU-9 has shown remarkable abilities to curb the early brain alterations associated with Alzheimer's disease, even before any symptoms rear their ugly head. This research shines a light on a fresh approach to tackling the illness at its very beginning stages, potentially halting the cognitive decline that devastates so many lives. Picture this: the drug targets subtle changes in the brain that set the stage for the disease, offering hope for prevention rather than just treatment.
Developed by innovative minds at Northwestern University, NU-9 has emerged as a strong candidate for early intervention in Alzheimer's. In this latest investigation, scientists pinpointed a previously unrecognized, extremely harmful form of amyloid beta oligomers—these are toxic clusters of tiny protein pieces that build up and cause trouble. These oligomers seem to kick off some of the brain's earliest disruptions, such as problems with neuron function, widespread inflammation, and the overactivation of immune cells.
NU-9, a compact small-molecule drug, effectively tackled this dangerous amyloid beta oligomer variant and slashed the harm it inflicts in a mouse model mimicking Alzheimer's. By tackling these issues right at the disease's start, the team believes NU-9 could block or greatly postpone the chain reaction of damaging events that eventually kills off brain cells. And this is the part most people miss—timing is everything in Alzheimer's, and starting treatment too late has doomed many past efforts.
Published in the prestigious Alzheimer's & Dementia: The Journal of the Alzheimer’s Association, the study highlights a new tactic for zeroing in on the disease when it's still in its infancy, long before symptoms like memory loss become evident. As Daniel Kranz, the lead author and a recent Ph.D. graduate from Northwestern's Interdisciplinary Biological Sciences program, explains: "Alzheimer's kicks in years, even decades, before you notice anything wrong. Think of it like a slow-building storm—toxic amyloid beta oligomers pile up in neurons and glial cells, and these brain support cells start reacting before any forgetfulness shows. By the time symptoms hit, the damage is deep. That's probably why so many trials flop—they're jumping in after the flood. Our experiment gave NU-9 before symptoms, catching it in that crucial pre-storm phase."
Kranz works under the guidance of William Klein, a top expert in Alzheimer's and a professor of neurobiology at Northwestern's Weinberg College of Arts and Sciences. Klein is also a co-founder of Acumen Pharmaceuticals, which is pushing a monoclonal antibody therapy in human trials aimed at the same oligomer subtype spotted in this study. Another key player is Richard Silverman, who created NU-9 and is a prominent chemist at Weinberg, where he holds the Patrick G. Ryan/Aon Professorship. Silverman, who earlier invented pregabalin (better known as Lyrica for treating conditions like fibromyalgia, nerve pain, and epilepsy), founded Akava Therapeutics to bring NU-9 (now called AKV9) to market.
The promise of NU-9
Dreamt up roughly 15 years back, NU-9 came from Silverman's long quest to find a small drug that could fend off harmful protein clumps in brain disorders. By 2021, it proved its worth in animal tests for amyotrophic lateral sclerosis (ALS), clearing out toxic proteins like SOD1 and TDP-43 and bringing upper motor neurons back to health. Fast-forward to 2024, and the FDA greenlit human trials for ALS. "Alzheimer's disease begins decades before its symptoms appear," Silverman notes, echoing the urgency of early detection.
Just this year, Silverman, Klein, and Kranz showed NU-9's potential for Alzheimer's in another study, where it cleared toxic amyloid beta oligomers from lab-grown brain cells in the hippocampus—that vital area for learning and memory. As Klein puts it: "In both ALS and Alzheimer's, cells get overwhelmed by poisonous protein piles. Normally, cells have a cleanup system, but it breaks down in these diseases. NU-9 fixes that rescue mechanism, saving the cell."
Early intervention
Eager to dig deeper into NU-9's power against Alzheimer's, the researchers tested it on mice before any disease signs appeared. The mice got a daily NU-9 dose by mouth for two months. The outcomes were eye-opening: NU-9 cut down on early reactive astrogliosis—a kind of brain inflammation that flares up way before symptoms do. It also dramatically lowered the toxic amyloid beta oligomers clinging to astrocytes, which are star-shaped brain cells that shield neurons and manage inflammation. Plus, levels of a twisted form of TDP-43 protein—often seen in brain-wasting diseases and tied to thinking problems—dropped sharply.
"These results are stunning," Klein exclaimed. "NU-9 had an outstanding effect on reactive astrogliosis, which is the essence of neuroinflammation and linked to the early stage of the disease." The benefits reached across various brain areas, hinting at NU-9's wide-reaching anti-inflammatory powers.
A hidden culprit
But here's where it gets controversial—while probing NU-9's effects, the team uncovered a surprise villain. For years, experts thought all amyloid beta oligomers were bad, especially compared to the bigger plaques that form later. But not so. The Northwestern group found one particularly nasty subtype. "We identified a distinct amyloid beta oligomer subtype that appears inside neurons and on nearby reactive astrocytes very early in the disease," Kranz said. "It potentially acts as an instigator of early Alzheimer’s pathology."
Dubbed ACU193+ because it's flagged by the ACU193 antibody, this subtype pops up first in stressed neurons, then seems to hop over to astrocytes. When it attaches, it might ignite a wave of inflammation that ripples through the brain, far ahead of memory lapses. NU-9 zeroed in on this subtype and wiped out much of it, positioning the drug as a star for ultra-early Alzheimer's prevention by possibly stopping astrocytes from going rogue.
Astrocytes are like the brain's first responders, but when they turn reactive, they become harmful—wrecking connections between neurons, spewing inflammatory chemicals, and speeding up brain cell death. Halting this could be a potent way to stall Alzheimer's march.
Kranz and Silverman compare this to proactive health strategies for other illnesses. "Most people are used to monitoring their cholesterol levels," Silverman said. "If you have high cholesterol, it doesn’t mean that you will have a heart attack soon. But it’s time to take drugs to lower your cholesterol levels to prevent that heart attack from happening down the road. NU-9 could play a similar role. If someone has a biomarker signaling Alzheimer’s disease, then they could start taking NU-9 before symptoms appear."
Klein adds: "There are a couple early diagnostic blood tests for Alzheimer’s disease in development. The promise of better early diagnostics—combined with a drug that could stop the disease in its tracks—is the goal."
Right now, the team is expanding tests to more Alzheimer's models, including one for late-onset disease that mirrors human aging better. They're also tracking animals longer to check if symptoms still emerge in treated groups and how early NU-9 use impacts memory and neuron vitality down the line.
Notes
This research received backing from the National Institutes of Health.
Silverman holds financial stakes in Akava Therapeutics. Klein has interests in Acumen Pharmaceuticals. Northwestern University also has financial ties (including shares and royalties) to both Akava Therapeutics and Acumen Pharmaceuticals.
What do you think? Could early drugs like NU-9 revolutionize Alzheimer's prevention, or are we overlooking risks in treating people before symptoms? Is the focus on oligomers too narrow—might there be other hidden triggers? Share your take in the comments; I'd love to hear if you agree, disagree, or have your own insights on this hot topic!
